Home > Haematology > ASH 2021 > Lymphoma > Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

Presented By
Dr Michael Bishop, University of Chicago, IL, USA
Conference
ASH 2021
Trial
Phase 3, BELINDA
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) as second-line treatment did not improve event-free survival (EFS) of patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma compared with standard-of-care [1]. These results of the phase 3 BELINDA study contradicts previous CAR T-cell therapy trials that have shown improved clinical outcomes. Tisa-cel, an autologous CAR T-cell therapy targeting CD19, is approved for patients with diffuse large B-cell lymphoma (DLBCL) after ≥2 lines of therapy [2,3]. Dr Michael Bishop (University of Chicago, IL, USA) presented the results of the BELINDA trial (NCT03570892), which enrolled 322 adults with confirmed R/R aggressive non-Hodgkin lymphoma within 12 months after first-line chemo-immunotherapy. All patients underwent leukapheresis for ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on